Browsing by Author Oriol, Albert

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2017Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Hajek, Roman; Ludwig, Heinz; Niesvizky, R.; Oriol, Albert; Orlowski, Robert Z; Central Clinical School: MedicineCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 10, 2017,pp 1327-1337
2017Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialTrotman, Judith; Dimopoulos, Meletios Athanassios; et al, Various; Heffner, L; Ma, Shuo; Macdonald, D; Matous, J; Oriol, Albert; Tam, Constantine; Tedeschi, A; Tournilhac, O; Concord Clinical School: MedicineIbrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial, The Lancet Oncology, vol.18, 2, 2017,pp 241-250